Relation between sulfonylurea therapy, complications, and outcome for elderly patients with acute myocardial infarction

American Heart Journal

Volumn 138, Issue 5 I, 1999, Pages

  Jollis, J G ^a   Simpson R J , Jr ^a   Cascio, W E ^a   Chowdhury, M K ^a   Crouse III, J R ^a   Smith S C , Jr ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORPROPAMIDE; GLIBENCLAMIDE; GLIPIZIDE; SULFONYLUREA DERIVATIVE; TOLBUTAMIDE;

ACUTE HEART INFARCTION; AGED; CARDIOGENIC SHOCK; CARDIOVASCULAR RISK; CONFERENCE PAPER; CONGESTIVE HEART FAILURE; DIABETES MELLITUS; FEMALE; HEART ARREST; HEART INFARCTION PREVENTION; HUMAN; MALE; PRIORITY JOURNAL;

EID: 0032744785     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-8703(99)70038-4     Document Type: Conference Paper

References (15)

1. A study of the effects of hypoglycemia agents on vascular complications in patients with adult-onset diabetes, VI: supplementary report on nonfatal events in patients treated with tolbutamide. Diabetes 1976;25:1129-53.
2. ATP blockade in type II diabetes and preconditioning in cardiovascular disease: time for reconsideration. Circulation 1996;94:2297-301.
3. Howes LG, Sundaresan P, Lykos D. Cardiovascular effects of oral hypoglycaemic drugs. Clin Exp Pharmacol Physiol 1996;23:201-6.
4. Cleveland JC, Meldrum DR, Cain BS, et al. Oral sulfonylurea hypoglycemic agents prevent ischemic preconditioning in human myocardium. Circulation 1997;96:29-32.
5. Lee KL, Woodlief LH, Topol EJ, et al. Predictors of 30-day mortality in the era of reperfusion for acute myocardial infarction: results from an international trial of 41,021 patients. Circulation 1995;91:1659-68.
6. Normand ST, Glickman ME, Sharma RG, et al. Using admission characteristics to predict short-term mortality from myocardial infarction in elderly patients. JAMA 1996;275:1322-8.
7. Feinglos MN, Bethel MA. Therapy of type 2 diabetes, cardiovascular mortality, and the UGDP. Am Heart J 1999;138:S346-52.
8. Seltzer HS. A summary of criticisms of the findings and conclusions of the University Group Diabetes Program (UGDP). Diabetes 1972;21:976-9.
9. Feinstein AR. How good is the statistical evidence against oral hypoglycemic agents? Adv Intern Med 1979;24:71-95.
10. Kolata GB. Controversy over study of diabetes drugs continues for nearly a decade. Science 1979;203:986-90.
11. Kilo C, Miller JP, Williamson JR. The crux of the UGDP: spurious results and biologically inappropriate data analysis. Diabetologia 1980;18:179-85.
12. Sartor G, Schersten B, Carlstrom S, et al. Ten-year follow-up of subjects with impaired glucose tolerance: prevention of diabetes by tolbutamide and diet regulation. Diabetes 1980;29:41-9.
13. Ohneda A, Maruhama Y, Itabashi H, et al. Vascular complications and long-term administration of oral hypoglycemic agents in patients with diabetes mellitus. Tohoku J Exp Med 1978;124:205-22.
14. Schotborgh CE, Wilde AAM. Sulfonylurea derivatives in cardiovascular research and in cardiovascular patients. Cardiovasc Res 1997;34:73-80.
15. Gerich JE. Oral hypoglycemic agents. N Engl J Med 1989;321:1231-45.